DK1401438T3 - Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer - Google Patents

Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer

Info

Publication number
DK1401438T3
DK1401438T3 DK01952097T DK01952097T DK1401438T3 DK 1401438 T3 DK1401438 T3 DK 1401438T3 DK 01952097 T DK01952097 T DK 01952097T DK 01952097 T DK01952097 T DK 01952097T DK 1401438 T3 DK1401438 T3 DK 1401438T3
Authority
DK
Denmark
Prior art keywords
cyclopamine
treatment
tumors
cell carcinoma
basal cell
Prior art date
Application number
DK01952097T
Other languages
Danish (da)
English (en)
Inventor
Sinan Tas
Oktay Avci
Original Assignee
Sinan Tas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1401438(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinan Tas filed Critical Sinan Tas
Application granted granted Critical
Publication of DK1401438T3 publication Critical patent/DK1401438T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK01952097T 2001-07-02 2001-07-02 Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer DK1401438T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (1)

Publication Number Publication Date
DK1401438T3 true DK1401438T3 (da) 2006-02-13

Family

ID=21619326

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01952097T DK1401438T3 (da) 2001-07-02 2001-07-02 Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer
DK02736467T DK1411938T3 (da) 2001-07-02 2002-04-19 Anvendelse af cyclopamin til fremstilling af et medikament til behandling af psoriasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02736467T DK1411938T3 (da) 2001-07-02 2002-04-19 Anvendelse af cyclopamin til fremstilling af et medikament til behandling af psoriasis

Country Status (14)

Country Link
EP (4) EP2862570A1 (enExample)
JP (3) JP2004536045A (enExample)
KR (1) KR20090125833A (enExample)
CN (2) CN1525859B (enExample)
AT (2) ATE305300T1 (enExample)
AU (1) AU2001272892B8 (enExample)
BR (1) BR0117063A (enExample)
CA (1) CA2452151C (enExample)
DE (2) DE60113733T2 (enExample)
DK (2) DK1401438T3 (enExample)
ES (3) ES2534400T3 (enExample)
PT (1) PT1411938E (enExample)
RU (1) RU2312661C2 (enExample)
WO (2) WO2002078703A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
ES2534400T3 (es) * 2001-07-02 2015-04-22 Sinan Tas Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
AU2006283040B2 (en) 2005-08-22 2011-08-25 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
PT2500360E (pt) 2005-10-31 2015-10-15 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
MY181496A (en) * 2006-10-31 2020-12-23 Government Of The United States Of America Represented By The Sec Dep Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
NZ579361A (en) * 2007-03-07 2012-04-27 Infinity Discovery Inc Heterocyclic cyclopamine analogs and methods of use thereof
US7964590B2 (en) 2007-03-07 2011-06-21 Infinity Discovery, Inc. Cyclopamine lactam analogs and methods of use thereof
EP3190121B1 (en) 2007-12-27 2019-02-20 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction of cyclopamine 4-en-3-one derivative
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
MX2011003183A (es) 2008-09-26 2011-04-21 Oncomed Pharm Inc Agentes que se unen a receptor encrespado y usos de los mismos.
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
HK1212216A1 (en) 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
HK1211887A1 (en) 2013-02-04 2016-06-03 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN104740633A (zh) * 2013-12-26 2015-07-01 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
WO2017139497A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
CA3227688A1 (en) 2021-09-13 2023-03-02 Sinan Tas Effective interventions with aging and diseases of aging of human and their consequences
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
US7098196B1 (en) * 1999-10-13 2006-08-29 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
WO1999052534A1 (en) * 1998-04-09 1999-10-21 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
ATE466850T1 (de) * 1998-09-23 2010-05-15 Res Dev Foundation Tocopherole, tocotrienole, sonstige chroman- und seitenkettenderivate, sowie deren verwendungen
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
AU780358B2 (en) * 1999-06-08 2005-03-17 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
EP1646395B8 (en) * 1999-11-30 2014-12-17 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
ES2534400T3 (es) * 2001-07-02 2015-04-22 Sinan Tas Uso de ciclopamina en el tratamiento de carcinoma de células basales y otros tumores

Also Published As

Publication number Publication date
DE60204966T2 (de) 2006-05-18
JP2004536045A (ja) 2004-12-02
CA2452151C (en) 2012-01-03
ATE305300T1 (de) 2005-10-15
BR0117063A (pt) 2004-07-27
WO2002078704A1 (en) 2002-10-10
EP1561464A3 (en) 2007-04-25
RU2004103074A (ru) 2005-05-10
DE60113733T2 (de) 2006-06-29
AU2001272892B2 (en) 2006-03-16
ES2534400T3 (es) 2015-04-22
DE60204966D1 (de) 2005-08-11
CN1525859B (zh) 2010-05-05
KR20090125833A (ko) 2009-12-07
WO2002078703A1 (en) 2002-10-10
ES2250434T3 (es) 2006-04-16
EP1561464A2 (en) 2005-08-10
PT1411938E (pt) 2005-11-30
AU2001272892B8 (en) 2006-05-04
DK1411938T3 (da) 2005-11-07
EP1401438B1 (en) 2005-09-28
JP2010132691A (ja) 2010-06-17
JP2014028834A (ja) 2014-02-13
EP2216022B1 (en) 2015-01-07
EP2862570A1 (en) 2015-04-22
EP2216022A1 (en) 2010-08-11
CN1525859A (zh) 2004-09-01
RU2312661C2 (ru) 2007-12-20
DE60113733D1 (de) 2006-02-09
CA2452151A1 (en) 2002-10-10
ES2246011T3 (es) 2006-02-01
WO2002078703A8 (en) 2003-06-12
JP5424923B2 (ja) 2014-02-26
CN1522146A (zh) 2004-08-18
ATE299022T1 (de) 2005-07-15
EP1401438A1 (en) 2004-03-31
CN1230169C (zh) 2005-12-07

Similar Documents

Publication Publication Date Title
DK1401438T3 (da) Anvendelse af cyclopamin i behandlingen af basalt cellecarcinom og andre tumorer
MA26973A1 (fr) Activateurs glucokinase isoindolin-1-one
NZ544472A (en) Compounds and therapeutical use thereof
EP1535610A4 (en) THERAPEUTIC CANCER
DE50310516D1 (de) Fredericamycin-derivate
ZA200103755B (en) Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby.
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
GB0121490D0 (en) Ciompounds
HRPK20041072B3 (hr) Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
AR028476A1 (es) Tratamiento del cancer
MY129310A (en) C-4 carbonate taxanes
DE60141194D1 (de) Behandlung des metastasierenden Karzinoms der Niere
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
GB0121494D0 (en) Compounds
IS2488B (is) Fyrirbygging á krabbameini í ristli og endaþarmi
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.
UY29136A1 (es) Uso de epotilonas en el tratamiento de metastasis osea
DK1385497T3 (da) Forebyggelse eller behandling af bryst-, prostata- og/eller halscancer med N,N-dimethylglycin
DE60003189D1 (de) Synergistische zusammensetzung, die daunorubicin derivate und antimetabolite enthält
MD1919G2 (ro) Remediu medicamentos